CDMO Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Avid Bioservices to GHO Capital Partners and Ampersand Capital Partners

Core Viewpoint - Wohl & Fruchter LLP is investigating the fairness of Avid Bioservices' proposed sale to GHO Capital Partners and Ampersand Capital Partners for $12.50 per share, which is below the $14.00 price target set by Wall Street analyst Paul Knight of KeyBanc [1][3]. Group 1 - Avid Bioservices has agreed to be sold for $12.50 per share in cash [2]. - The investigation focuses on whether the Avid Board of Directors acted in the best interests of shareholders and if the sale price is fair [3]. - The law firm is also examining if all material information regarding the transaction has been fully disclosed [3].